Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Health Economic Impact and Highlighted Clinical/Safety Outcomes in 300 Relapsing Multiple Sclerosis Patients Treated with Alemtuzumab in a Single MS Center
Multiple Sclerosis
P10 - Poster Session 10 (11:45 AM-12:45 PM)
6-004

The greatest health expenditure for patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in the US is Disease Modifying Therapy (DMT). Alemtuzumab has a unique treatment regimen, allowing for potential significant cost burden reduction, while providing high treatment efficacy.

To describe DMT cost expenditure and clinical/safety outcomes in a single MS center of an Alemtuzumab cohort of 300 relapsing patients.

The first 300 evaluable RRMS patients treated with Alemtuzumab at the Joanne P LaGanke MS Center are described in terms of baseline characteristics, clinical, MRI, and safety outcomes, and DMT cost savings based on annual WAC costs for all other DMT per time point.

Of the 300 subjects, 81% are still followed consistently in clinic. The projected DMT cost savings to date with this cohort exceeds $150,000,000. Of the patients not currently followed at the clinic, most moved, while 18 died. A Listeria meningitis death was the only direct attributable death known to the treatment. Two COVID-related deaths far removed from the treatment occurred. The safety outcomes mirrored those seen in the clinical trials with Alemtuzumab. Sixty percent of the patients had sustained EDSS improvement over the nine-year period of follow-up. Less than ten percent had clinically sustained worsening.

Alemtuzumab administered in this population of RRMS patients provided a massive health cost reduction from DMT use, while maintaining excellent overall clinical outcomes. No unexpected safety issues were observed.

Authors/Disclosures
Ryan Shannon, NP (North Central Neurology Associates)
PRESENTER
Mr. Shannon has received personal compensation for serving as an employee of EMD Serono. Mr. Shannon has received personal compensation for serving as an employee of Biogen Idec. Mr. Shannon has received personal compensation for serving as an employee of TG Therapeutics. Mr. Shannon has received personal compensation for serving as an employee of EMD Serono. Mr. Shannon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Mr. Shannon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Mr. Shannon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Mr. Shannon has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for EMD Serono. Mr. Shannon has a non-compensated relationship as a Consultant with EMD Serono that is relevant to AAN interests or activities.
Christopher C. LaGanke, MD (North Central Neurology Associates, PC) Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. LaGanke has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi. Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GSK. Dr. LaGanke has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Serono EMD. Dr. LaGanke has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. LaGanke has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. LaGanke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics.
Jim Browen (North Central Neurology) Jim Browen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech.